Please login to the form below
GVAX
This page shows the latest GVAX news and features for those working in and with pharma, biotech and healthcare.
Aduro pancreatic cancer vaccine trial disappoints
The immunotherapy combines CRS-207 - a drug that promotes the expression of the tumour-associated antigen mesothelin - with an immune-boosting GVAX cell line, and is Aduro's lead product candidate. ... Aduro is not giving up on the CRS-207/GVAX vaccine
Latest news
-
Pfizer's Bosulif gets conditional green light for CML in Europe
mechanism of action than the current crop of treatments, as well as Cephalon/Hospira's Omapro (omacetaxine), BioSante Pharma's GVAX and Deciphera's ABL inhibitor rebastinib (DCC-2036).
-
Combating cancer
Vaccines such as CancerVax (Canvaxin), Genitope Corp (MyVax personalised immunotherapy), Favrille Inc (FavId), Therion (Panvac), CG 8123 (Gvax; Cell Genesys) have not been as successful, and development of these vaccines has
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
Latest Intelligence
-
Cancer immunotherapy: What's on the horizon?
marked more by failures than successes, with a string of candidates (including Aduro’s GVAX, CancerVax’ Canvaxin, and Genitope’s MyVax) missing the mark in late-stage testing.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- Sanofi's frexalimab shows promise in relapsing forms of MS
- BMS presents positive four-year results for Opdivo combination in lung cancer
- Pfizer reports positive results for elranatamab in multiple myeloma
- Amgen reports positive results for Otezla in psoriatic arthritis
- Merck sues US government over Medicare drug price negotiation programme
- GSK’s RSV vaccine approved by EC for older adults
- The 17th World Congress on Controversies in Neurology
- Medscape Education is Focusing on Patient Centricity and Education Outcomes at EHA 2023
- Pfizer reports positive results for elranatamab in multiple myeloma
- Amgen’s Lumakras shows promise in phase 3 lung cancer study
No results were found
PMHub
Hanover Communications
Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...
Latest intelligence
- The 17th World Congress on Controversies in Neurology
- This year, there was a focus on the rare disease neuromyelitis optica spectrum disorder that strikes suddenly and mainly impacts women...
- Archetypes: Rethinking go-to-market expectations to drive commercial success
- In this white paper, our consultants analyze trends spanning global policy developments, rising inflation, and increasingly complex customer journeys, and reveal a new data-driven approach to archetyping that crystalizes the...
- Tuberculosis – why it remains a major global public health challenge
- Innovative collaboration is required to address the major public health challenges around TB and expedite drug development...
